Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S A Berry

Showing results (91-100 of 94) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 94 results.
Nature Genetics|November 5, 1997
Mutations in transcriptional regulator ATRX establish the functional significance of a PHD-like domainR J Gibbons, S Bachoo, D J Picketts, et al.
Molecular Genetics and Metabolism|November 21, 2015
Glutamine and hyperammonemic crises in patients with urea cycle disordersB Lee, G A Diaz, W Rhead, et al.
Molecular Genetics and Metabolism|October 23, 2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratioM Mokhtarani, G A Diaz, W Rhead, et al.
Molecular Genetics and Metabolism|September 11, 2012
Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disordersM Mokhtarani, G A Diaz, W Rhead, et al.
Pageof 10

Showing results (91-100 of 94) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 94 results.
Nature Genetics|November 5, 1997
Mutations in transcriptional regulator ATRX establish the functional significance of a PHD-like domainR J Gibbons, S Bachoo, D J Picketts, et al.
Molecular Genetics and Metabolism|November 21, 2015
Glutamine and hyperammonemic crises in patients with urea cycle disordersB Lee, G A Diaz, W Rhead, et al.
Molecular Genetics and Metabolism|October 23, 2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratioM Mokhtarani, G A Diaz, W Rhead, et al.
Molecular Genetics and Metabolism|September 11, 2012
Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disordersM Mokhtarani, G A Diaz, W Rhead, et al.
Pageof 10